Mon Sep 23 22:30:45 UTC 2024: ## Perrigo Stock Remains “Hold” Despite Strong Earnings Report

**New York, NY -** Perrigo (NYSE:PRGO) saw its stock rating reaffirmed as a “hold” by Jefferies Financial Group on Monday, despite the company exceeding earnings expectations in its most recent quarter. Jefferies Financial Group also lowered their price objective for Perrigo from $50.00 to $30.00, suggesting a potential upside of 10.82% from its current price.

Perrigo reported $0.53 earnings per share (EPS) for the quarter ending August 2nd, surpassing the consensus estimate of $0.46 by $0.07. However, the company’s revenue fell short of expectations at $1.07 billion, compared to the estimated $1.13 billion. While revenue declined by 10.7% year-over-year, Perrigo’s positive return on equity (6.79%) and a negative net margin of 2.81% might indicate some positive trends for the company.

Analysts are optimistic about Perrigo’s future, with an average rating of “Moderate Buy” and an average target price of $37.00. This suggests that several analysts believe the stock is currently undervalued and could potentially increase in price.

However, recent insider trading activity has raised some concerns. Director Katherine C. Doyle sold 8,954 shares on September 13th, while EVP Ronald Craig Janish sold 13,000 shares on August 26th. This insider selling, combined with the revised price objective from Jefferies Financial Group, may be contributing to the “hold” rating.

Perrigo is a leading provider of over-the-counter health and wellness solutions, operating in the United States, Europe, and internationally. The company’s product portfolio spans a wide range of self-care categories, including respiratory, nutrition, digestive health, pain relief, and oral care.

Despite the mixed signals from analysts and insiders, Perrigo’s strong earnings performance suggests a positive trajectory for the company. Whether the stock will ultimately rise or fall remains to be seen, but it’s clear that Perrigo continues to be a company worth watching in the healthcare market.

Read More